SAMSUNG BIOEPIS

Passion for Health

We are finding smarter, faster ways of delivering quality-assured medicines to the people who need them

Learn More

We use innovative science to unlock
the healthcare of the future

Our Mission We want to enhance the lives of patients through our pioneering and innovative use of science and technology

Learn More
Our Products Our first-wave biosimilars focus on key therapy areas in immunology and oncology

Learn More
Our Pipeline Our pipeline is now expanding into new therapy areas including ophthalmology, gastroenterology, and hematology

Learn More

News & Stories

Learn more about our latest news and stories of
Samsung Bioepis

NEWS

Kyung-Ah Kim Named as President and Chief Executive Officer ...: Samsung Bioepis Co., Ltd. today announced that Kyung-Ah Kim,...

Nov 27, 2024

NEWS

Samsung Bioepis and Biogen Receive European Commission (EC) ...: Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) tod...

Nov 18, 2024

NEWS

Samsung Bioepis Receives Positive CHMP Opinion for Denosumab...: Samsung Bioepis Co., Ltd. today announced that the European ...

Nov 15, 2024

NEWS

Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Re...: Samsung Bioepis Co., Ltd. today released its Fourth Quarter ...

Oct 10, 2024

NEWS

Samsung Bioepis Presents Totality-of-the-Evidence Supporting...: Samsung Bioepis Co., Ltd. today presented the “totality-of-t...

Sep 23, 2024

NEWS

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for...: Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) tod...

Sep 20, 2024

We are proud to announce that Kyung-Ah Kim has been named as President and CEO of Samsung Bioepis. As the first non-founder female CEO in Samsung’s history, Kim...

Nov 27, 2024

In a newest blog post, Joseph Park, Senior Manager, Regulatory Affairs/Regulatory Strategy and Policy, discusses acknowledging global reference products to help...

Nov 25, 2024

Although biosimilars are drugs that are meant to be clinically similar to reference products, the two drug types each go through different assessments to prove ...

Nov 20, 2024

We are continuing our work to expand access to quality-assured, safe and effective biosimilars to improve patient’s quality of life and support sustainability o...

Nov 18, 2024

Our own Gillian Woollett co-authored a scientific article about streamlining the development of biosimilars. Their recommendations target savings in costs and t...

Nov 15, 2024

For #GlobalBiosimilarsWeek next week, we’re focusing on this year’s theme, Advancing Access to Biosimilars. Stay tuned for a blog post about the importance of e...

Nov 7, 2024

We are proud to announce that Kyung-Ah Kim has been named as President and Chief Executive Officer of Samsung Bioepis. As the first non-founder female Chief Exe...

Nov 27, 2024

In our newest blog post, our own Joseph P. Park, Senior Manager, Regulatory Affairs/Regulatory Strategy and Policy, discusses acknowledging global reference pro...

Nov 25, 2024

Although biosimilars are drugs that are meant to be clinically similar to reference products, the two drug types each go through different assessments to prove ...

Nov 20, 2024

We are continuing our work to expand access to quality-assured, safe and effective biosimilars to improve patient’s quality of life and support sustainability o...

Nov 18, 2024

Gillian Woollett, VP, Head of Regulatory Strategy and Policy at Samsung Bioepis, co-authored a scientific article in BioDrugs last year about streamlining the d...

Nov 15, 2024

Developing biosimilars more efficiently could change so many patients’ lives by ensuring they have wider and more timely access to biologicals. For #GlobalBiosi...

Nov 13, 2024

Join Us

Our work has only just begun. Do you want to help us
overcome the barriers patients face in accessing
quality-assured, affordable medicines?
Read more about working at Samsung Bioepis.

Learn More

PRIVACY NOTICE COOKIE POLICY TERMS OF USE COMMUNITY GUIDELINES SECURITY REPORTING BUSINESS ETHICS COMPLIANCE SITEMAP

twitter linkedin

This site uses cookies to analyze traffic as described in our Cookie Policy.
Please click the “ACCEPT” button or continue to use our site if you agree to our use of cookies.

You are now leaving the Samsung Bioepis website.
Do you wish to continue?

레이어 팝업 닫기